Evidence map›Paper›PMID 37048066›Full record

ArticleCells2023

Rapamycin Alleviates Protein Aggregates, Reduces Neuroinflammation, and Rescues Demyelination in Globoid Cell Leukodystrophy.

Dar-Shong Lin, Yu-Wen Huang, Tsung-Han Lee, Lung Chang, Zon-Darr Huang, Tsu-Yen Wu, Tuan-Jen Wang, Che-Sheng Ho

Open access · goldAbstract read
In one paragraph

Article in Cells, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
2.5field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 14 citations in OpenAlex.

  1. Review
  2. Nutrition as a systems regulator of brain aging trajectories.Frontiers in molecular neuroscience · 2026
    Review
  3. Article
  4. Article
  5. Review
  6. Review
  7. Article
  8. Article
  9. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 1 institution in 1 country.

Dar-Shong LinDepartment of Pediatrics, MacKay Memorial Hospital, Taipei 10449, Taiwan.
Yu-Wen HuangDepartment of Medical Research, MacKay Memorial Hospital, Taipei 10449, Taiwan.
Tsung-Han LeeDepartment of Medical Research, MacKay Memorial Hospital, Taipei 10449, Taiwan.
Lung ChangDepartment of Pediatrics, MacKay Memorial Hospital, Taipei 10449, Taiwan.
Zon-Darr HuangDepartment of Medical Research, MacKay Memorial Hospital, Taipei 10449, Taiwan.
Tsu-Yen WuDepartment of Medical Research, MacKay Memorial Hospital, Taipei 10449, Taiwan.
Tuan-Jen WangDepartment of Laboratory Medicine, MacKay Memorial Hospital, Taipei 10449, Taiwan.
Che-Sheng HoDepartment of Medicine, MacKay Medical College, New Taipei 25245, Taiwan.
Mackay Memorial Hospital · TW

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

We have shown in vivo and in vitro previously that psychosine causes dysfunction of autophagy and the ubiquitin-proteasome system underlying the pathogenesis of globoid cell leukodystrophy (GLD), a devastating lysosomal storage disease complicated by global demyelination. Here, we investigated the therapeutic efficacy of the mTOR inhibitor rapamycin in twitcher mice, a murine model of infantile GLD, in biochemical, histochemical, and clinical aspects. Administration of rapamycin to twitcher mice inhibited mTOR signaling in the brains, and significantly reduced the accumulation of insoluble ubiquitinated protein and the formation of ubiquitin aggregates. The astrocytes and microglia reactivity were attenuated in that reactive astrocytes, ameboid microglia, and globoid cells were reduced in the brains of rapamycin-treated twitcher mice. Furthermore, rapamycin improved the cortical myelination, neurite density, and rescued the network complexity in the cortex of twitcher mice. The therapeutic action of rapamycin on the pathology of the twitcher mice's brains prolonged the longevity of treated twitcher mice. Overall, these findings validate the therapeutic efficacy of rapamycin and highlight enhancing degradation of aggregates as a therapeutic strategy to modulate neuroinflammation, demyelination, and disease progression of GLD and other leukodystrophies associated with intracellular aggregates.

Indexed as

Demyelinating DiseasesLeukodystrophy, Globoid CellAnimalsGalactosylceramidaseMiceNeuroinflammatory DiseasesProtein AggregatesSirolimusTOR Serine-Threonine KinasesUbiquitinsGalactosylceramidaseProtein AggregatesSirolimusTOR Serine-Threonine KinasesUbiquitinsautophagydemyelinationgloboid cell leukodystrophyKrabbe diseaseneuroinflammationpsychosineubiquitin-proteasome system

Identifiers

PMID37048066
PMCPMC10093124
OpenAlexW4360857235

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.